• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Glenn Gormley - Articles and news items

Daiichi Sankyo logo

Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA

Industry news / 9 January 2014 / Daiichi Sankyo

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism…

Daiichi Sankyo logo

Daiichi Sankyo submits edoxaban Marketing Authorisation Application to the EMA for once-daily use for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism

Industry news / 8 January 2014 / Daiichi Sankyo

Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation…

Daiichi Sankyo logo

Daiichi Sankyo submits supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for new indications

Industry news / 19 December 2013 / Daiichi Sankyo Company

Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism…

Daiichi Sankyo logo
Daiichi Sankyo logo
Daiichi Sankyo logo

Daiichi Sankyo and Amplimmune announce strategic alliance to develop AMP-110 therapy

Industry news, News / 8 January 2013 / Daiichi Sankyo

Daiichi Sankyo & Amplimmune have entered into a broad strategic collaboration…

Daiichi Sankyo logo

Daiichi Sankyo completes enrolment in Hokusai-VTE

Industry news, News / 25 October 2012 / Daiichi Sankyo

Edoxaban is an investigational, once daily, novel oral factor Xa inhibitor…

Lilly-Logo

Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure

Industry news, News / 26 August 2012 / Eli Lilly and Company

Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population…

Daiichi Sankyo logo

ArQule and Daiichi Sankyo announce completion of patient recruitment in Phase 3 clinical trial of Tivantinib in non-small cell lung cancer

Industry news, News / 18 May 2012 / Daiichi Sankyo

ArQule and Daiichi Sankyo announced that recruitment of patients has been completed…

Daiichi Sankyo logo

FDA approval of Zelboraf(TM) (vemurafenib) establishes oncology foothold in US for Daiichi Sankyo

Industry news, News / 17 August 2011 / Daiichi Sankyo

First-in-class treatment option soon available to treat deadly form of skin cancer…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +